The objective of the NIMH Toxicological Evaluation of Novel Ligands program is to advance the discovery of biomarkers by accelerating the development and application of novel ligands for PET, SPECT, and MRI imaging in humans by providing toxicology and safety assessment of promising, target-selective compounds. The program also provides limited assessment of novel psychoactive agents for clinical research and as potential therapeutics. Toxicology and safety data generated by the program are used to support Investigational New Drug (IND) applications to the Food and Drug Administration (FDA) by investigators, or for Radioactive Drug Research Committee (RDRC) evaluation of a compound for human studies. The program will also provide access to toxicology consultation services and support for initial in vitro and early stage in vivo toxicity testing for promising lead compounds from NIMH-relevant ligand and therapeutics development projects.

Agency
National Institute of Health (NIH)
Type
Research and Development Contracts (N01)
Project #
271200900018C-11-0-1
Application #
8659281
Study Section
Project Start
2012-06-30
Project End
2013-06-29
Budget Start
Budget End
Support Year
Fiscal Year
2013
Total Cost
$356,094
Indirect Cost
Name
Sri International
Department
Type
DUNS #
009232752
City
Menlo Park
State
CA
Country
United States
Zip Code
94025